ArticleBiomedical reports2025
Cardiac function and mortality of stem cell therapy in patients with coronary artery disease who underwent coronary artery bypass graft without heart failure: A meta-analysis.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD) is a common disease and can be treated with coronary artery bypass grafting (CABG) in specific cases. Stem cell therapy has been shown to be effective in patients with CAD who underwent CABG in several settings but limited to those without heart failure. The aim of the present study was to evaluate whether stem cell therapy is effective in patients with CAD who underwent CABG and had no heart failure. The present systematic review investigated wether there was any improvement in cardiac function or reduction of mortality in patients with CAD who received CABG and did not have heart failure. The types of studies included in this systematic review were randomized controlled trials. In total, four databases were used for a systematic search: PubMed, CENTRAL database, Scopus, and CINAHL Plus. The results were reported as the mean difference of left ventricular ejection fraction (LVEF) and risk ratio of mortality rate between stem cell therapy vs. controls. There were 125 studies retrieved from a search in the four aforementioned databases; of those, seven studies met the study criteria. Regarding the outcome of cardiac function, the standardized mean difference of LVEF between the experimental and the control groups was 0.17 (95% CI: -0.09, 0.44). The risk ratio of mortality was also not statistically significant (1.59; 95% CI: 0.68, 3.73). Stem cell therapy did not exert significant improvement of the LVEF or the mortality rate compared with controls, in patients with CAD who underwent CABG and had no heart failure. Further studies are required to confirm the results of the present study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.